89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and Longitude Capital. RA Capital Management

Read the full 404 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE